Table 2.
Biopsy pathology and first treatment.
| No cancer detected by biopsy (n = 119) | ||||
|---|---|---|---|---|
| Pathology | Fibroadenoma | Othera | No data | |
| n (%) | 34 (29) | 31 (26) | 54 (45) | |
| Invasive cancer by biopsy (n = 140) | ||||
|---|---|---|---|---|
| Pathology | DCIS | IDC | ILC | Other |
| n (%) | 12 (8.6) | 111 (79) | 12 (8.6) | 5 (3.6) |
| Tumor size (T) | ||||
| Tis/0 | 7 | |||
| 1 | 3 | 57 | 5 | 3 |
| 2 | 30 | 5 | 2 | |
| 3 | 6 | |||
| 4 | 4 | |||
| Missing data | 2 | 3 | 1 | |
| Lymph node (N) | ||||
| 0 | 12 | 59 | 5 | |
| 1 | 29 | 6 | ||
| 2 | 5 | 3 | ||
| 3 | 6 | 1 | ||
| Missing data | 12 | 2 | ||
| Metastatic (M) | 10 | 1 | ||
| Grade | ||||
| 1 | 3 | 16 | 2 | |
| 2 | 14 | 1 | 1 | |
| 3 | 2 | 12 | ||
| Missing data | 7 | 69 | 9 | 4 |
| Stage | ||||
| 0 | 8 | |||
| 1 | 4 | 42 | 5 | 3 |
| 2 | 45 | 4 | 2 | |
| 3 | 7 | 1 | ||
| 4 | 10 | 1 | ||
| Missing data | 7 | 1 | ||
| Receptor status | ||||
| HER2− PR/ER− | 3 | 8 | ||
| HER2− PR/ER+ | 4 | 74 | 11 | 4 |
| HER2+ PR/ER− | 1 | 7 | ||
| HER2+ PR/ER+ | 3 | 19 | 1 | |
| Missing data | 1 | 3 | 1 | |
| First treatment | ||||
| Surgery | 12 | 68 | 11 | 5 |
| Neoadjuvant | 29 | |||
| Chemotherapy | 14 | 1 | ||
| Hormonal | 2 | |||
DCIS ductal carcinoma in-situ, IDC invasive-ductal carcinoma, ILC invasive-lobular carcinoma, HER2 human epidermal growth factor receptor, ER/PR estrogen/progesterone receptor.
aOther pathological findings include fibrocystic changes, fat necrosis, adenosis, and sclerosis.